Wells Pharma of Houston: multiple injections
Wells Pharma recalls injectable drugs (phenylephrine, fentanyl, ketamine) over cGMP deviations.
Consumers and healthcare providers should immediately check their inventory for the affected products and stop using them. Contact Wells Pharma of Houston for instructions on returning the products and for further guidance.
Why it was recalled
Wells Pharma of Houston is recalling multiple injectable drug products, including phenylephrine, fentanyl citrate, and ketamine hydrochloride solutions, due to cGMP deviations. The products may not meet quality standards, posing a risk to patients.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
| Product | Strength | NDC / UPC | UPC | Recall # |
|---|---|---|---|---|
| fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride | 1000 mcg | NDC 73702-203-65 | – | D-0506-2026 |
| Ketamine Hydrochloride Injectable Solution | 50 mg | NDC 73702-302-31 | – | D-0507-2026 |
| fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride, Narcotic, ( | 2500 mcg | – | 02182202030398 | D-0504-2026 |
| fentaNYL Citrate Injectable Solution, NARCOTIC, Cii | 1000 mcg | NDC 73702-202-02 | – | D-0503-2026 |
| Phenylephrine Hydrochloride Injectable Solution | 40 mg | NDC 73702-122-03 | – | D-0502-2026 |
| fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride | 50 mcg | NDC 73702-202-15 | – | D-0508-2026 |
| fentaNYL Citrate Injectable Solution, Narcotic, CII | 1250 mcg | NDC 73702-204-25 | – | D-0505-2026 |
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Editorial summary by Recall Canary · summary updated 2026-09-08 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification